Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huairu Granules plus chemotherapy and PD-1 inhibitor for first-line extensive-stage small cell lung cancer
ChiCTR2500114626Phase 4Not yet recruiting
- Sponsor
- Huzhou Central Hospital
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of huai'er granules in small cell lung cancer (SCLC), sponsored by Huzhou Central Hospital. Primary endpoint: Progression-free survival (PFS) by investigator assessment. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
huai'er granules
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500114626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114626.